Testing TQH3906 for active psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests a new capsule, TQH3906, for people with active psoriatic arthritis who haven't had success with other treatments. It aims to see if the drug is safe and works well for joint and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with psoriatic arthritis for at least 3 months and currently have active joint pain and swelling.
- You have tried at least one previous treatment that didn't work well or caused side effects.
- You are willing to use birth control during the study and for 6 months after (if applicable).
- You do not have other autoimmune diseases (like rheumatoid arthritis) or active infections like tuberculosis or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This study tests an oral medicine called zasocitinib for people with psoriatic arthritis who have not had enough relief from other treatments. It may help reduce joint pain and skin symptoms.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.